Efficacy and Safety of Daratumumab

Systematic review and meta-analysis of the efficacy and safety of ...

There were six studies (869 patients) that evaluated the efficacy of daratumumab for the treatment of RRMM based on the ORR and at least VGPR [5 ...

DARZALEX® (daratumumab)-SC based quadruplet regimen ...

[4] PERSEUS is an ongoing, randomised, open-label, Phase 3 study comparing the efficacy and safety of daratumumab-VRd and autologous stem ...

FDA approves daratumumab and hyaluronidase-fihj with bortezomib ...

Full prescribing information for Darzalex Faspro will be posted on Drugs@FDA. Efficacy and Safety. Efficacy was evaluated in PERSEUS ...

Real-world data on the efficacy and safety of daratumumab ... - CORE

Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety ...

Campus ALL updates: the safety and efficacy of daratumumab for ...

Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, shares some results from a study evaluating the safety and efficacy of ...

based Regimens in Chinese Patients With Multiple Myeloma

Patterns, Efficacy, and. Safety of Daratumumab- based Regimens in. Chinese Patients With. Multiple Myeloma: An Updated Analysis of the MMY4032 Study. Luqun ...

Subcutaneous daratumumab: combining efficacy, safety ... - YouTube

... safety compared to IV administration, and encouraging efficacy data ... Subcutaneous daratumumab: combining efficacy, safety & convenience.

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

In 2020, subcutaneous (SC) daratumumab was approved for the treatment of multiple myeloma, and randomized data suggest a lower rate of IRRs compared with IV ...

A Study of the Efficacy and Safety of Monotherapy With BCD-264 ...

The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for ...

Evaluating Daratumumab in the Treatment of Multiple Myeloma

A phase II trial from Dana Farber is currently evaluating the efficacy of daratumumab for the treatment of high-risk MGUS or low-risk smoldering ...

P-163: efficacy and safety of Daratumumab, Bortezomib, Melphalan ...

Scolaris Language Selector Scolaris Language Selector ... Cochrane Review language. Select your preferred language for Cochrane Reviews and other content.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

The overall safety profile of D-VRd was consistent with the known safety profiles for DARZALEX FASPRO® and VRd. ... efficacy and safety of ...

HCP Website | DARZALEX® (daratumumab) & DARZALEX ...

View the official healthcare professional (HCP) website for DARZALEX® & DARZALEX FASPRO®. See full Prescribing & Safety Information.

Clinical Trials - Mayo Foundation for Medical Education and Research

The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with ...

Research Shows Daratumumab's Effectiveness in AL Amyloidosis

Recent Cleveland Clinic Cancer Center research shows the monoclonal antibody daratumumab is a safe, effective and fast-acting treatment for ...

Full article: Efficacy and safety of weekly carfilzomib (70 mg/m2 ...

EQUULEUS is a phase 1 b, multicenter, open-label, multiarm, non-randomized study of daratumumab in combination with other agents in patients ...

Addition of daratumumab to multiple myeloma backbone regimens ...

Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone ...

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide ...

Findings In this nonrandomized clinical trial, the primary end point (minimal residual disease negativity) was achieved in 29 of 41 patients, ...

Trials for DARZALEX FASPRO

In a pooled safety population of 1249 patients with multiple myeloma (N=1056) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO® as ...

Daratumumab-Based Treatment for Immunoglobulin Light-Chain ...

In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and ...